UCB Stock Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 42.54B 49.18B 39.72B 36.44B 68.54B 4,680B 69.63B 466B 183B 2,346B 185B 181B 7,755B | P/E 2026 * |
22.7x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 42.71B 49.38B 39.89B 36.59B 68.82B 4,699B 69.91B 468B 184B 2,355B 185B 181B 7,787B | EV / Sales 2026 * |
4.94x | EV / Sales 2027 * | 4.19x |
| Free-Float |
61.59% | Yield 2026 * |
0.65% | Yield 2027 * | 0.67% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 49.18B | |
| +1.59% | +2.85% | +39.32% | -0.16% | 78.32B | |
| +2.77% | +4.78% | -0.98% | +26.82% | 51.1B | |
| +0.94% | +1.72% | +20.69% | +176.66% | 49.18B | |
| +1.72% | +8.18% | -49.03% | -49.18% | 44.71B | |
| +0.80% | +2.46% | +59.13% | -23.35% | 30.72B | |
| +1.84% | +0.87% | +53.80% | +84.29% | 24.44B | |
| +9.86% | +7.94% | +126.53% | -41.89% | 23.62B | |
| +2.58% | +13.14% | +8.17% | +202.17% | 21.05B | |
| -0.02% | +3.99% | +66.08% | +116.11% | 16.61B | |
| Average | +2.17% | +4.08% | +35.97% | +54.61% | 37.75B | |
| Weighted average by Cap. | +1.87% | +4.29% | +27.21% | +42.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.65B 10B 8.08B 7.41B 13.94B 952B 14.16B 94.78B 37.2B 477B 37.55B 36.73B 1,577B | 9.7B 11.21B 9.06B 8.31B 15.63B 1,067B 15.88B 106B 41.71B 535B 42.11B 41.19B 1,768B |
| Net income | 1.87B 2.16B 1.75B 1.6B 3.02B 206B 3.07B 20.52B 8.05B 103B 8.13B 7.95B 341B | 2.34B 2.71B 2.19B 2.01B 3.77B 258B 3.83B 25.66B 10.07B 129B 10.17B 9.94B 427B |
| Net Debt | 174M 202M 163M 149M 281M 19.2B 286M 1.91B 750M 9.62B 757M 741M 31.81B | -1.94B -2.24B -1.81B -1.66B -3.13B -213B -3.18B -21.26B -8.34B -107B -8.42B -8.24B -354B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
